Effects of long-term low-dose mifepristone on reproductive function in women
article
OA: bronze
CC0
⤵ 14 in-corpus citations
Abstract
Low-dose antiprogestin administration has been proposed as a new contraceptive modality to interference with endometrial receptivity without disturbing ovarian function. The effects of 1 mg/day mifepristone for 150 days on the menstrual cycle were assessed in 21 surgically sterilized women. The aim was to study each woman for one control cycle and during months 1, 3 and 5 of treatment. Ovulation, endometrial thickness, serum oestradiol and progesterone, urinary luteinizing hormone, endometrial morphology and cervical mucus were assessed. Luteal phase progesterone concentrations were observed in 36 of the 60 treated months assessed and less frequently as treatment progressed. The bleeding pattern was regular in most biphasic cycles, while prolonged interbleeding intervals or no bleeding were associated with monophasic cycles. Altered endometrial morphology was found in all cases irrespective of the occurrence of luteal activity. Increased endometrial thickness and dilated glands were observed in 25 and 34% respectively of the monophasic cycles. Mifepristone, 1 mg/day, interferes with endometrial development while allowing the occurrence of biphasic ovarian cycles and regular bleeding. However, it also prevents ovarian cyclicity in a high proportion of treated months, and this is associated with increased endometrial growth in some women, which may be of concern.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (13)
- Antiprogestins: Mechanism of Action and Contraceptive via openalex
- Dating the Endometrial Biopsy via openalex
- Pharmacokinetics of mifepristone after low oral doses via openalex
- W2132932197 via openalex
- W2138086034 via openalex
- W2170049035 via openalex
- W2199876988 via openalex
- W2259750020 via openalex
- W2272860517 via openalex
- W376034035 via openalex
- W2616973505 via openalex
- W1973948212 via openalex
- W2013000621 via openalex
Cited by (14)
- Mifepristone increases AQP1 mRNA expression, angiogenesis, and cell permeability through the ERK MAPK pathway 2022
- Physiology of the Endometrium and Regulation of Menstruation 2020
- Mifepristone: where do we come from and where are we going? 2010
- Progesterone receptor modulators and the endometrium: changes and consequences† 2007
- Progesterone receptor antagonists and selective progesterone receptor modulators: proven and potential clinical applications 2007
- Inhibition of Proliferation of Endometrial Stromal Cells by Trichostatin A, RU486, CDB-2914, N-Acetylcysteine, and ICI 182780 2006
- The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women 2005
- Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications 2005
- Effects of Hormones 2005
- Effect of long-term treatment with low-dose mifepristone on the endometrium 2003
- Progesterone antagonists and progesterone receptor modulators: an overview 2003
- Daily Low-Dose Mifepristone Has Contraceptive Potential by Suppressing Ovulation and Menstruation: A Double-Blind Randomized Control Trial of 2 and 5 mg per Day for 120 Days 2002
- Progesterone receptor modulators and progesterone antagonists in women's health 2000
- Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus 1998
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK